This decrease in BCL‐2 family protein levels may serve as a mechanism by which this AML cell line can become re‐sensitized to venetoclax following combination treatment with 225Ac‐lintuzumab (Figure 4 and Figure S3). This evidence concerns the gene BCL2 and acute myeloid leukemia.